JY
IKT icon

Jeff Yass’s Inhibikase Therapeutics IKT Stock Holding History

Jeff Yass’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33K Sell
16,242
-18,858
-54% -$33.8K ﹤0.01% 12940
2026
Q1 		$59K Buy
35,100
+13,568
+63% +$24.1K ﹤0.01% 12592
2025
Q4 		$44.1K Sell
21,532
-24,073
-53% -$38.3K ﹤0.01% 11790
2025
Q3 		$73.9K Sell
45,605
-337,466
-88% -$585K ﹤0.01% 11719
2025
Q2 		$747K Sell
383,071
-121,554
-24% -$238K ﹤0.01% 8193
2025
Q1 		$1.11M Buy
+504,625
New +$1.27M ﹤0.01% 6993
2024
Q2 		– Sell
-22,616
Closed -$48.9K – 12594
2024
Q1 		$48.9K Buy
+22,616
New +$49.9K ﹤0.01% 11572
2023
Q1 		– Sell
-5,109
Closed -$15.3K – 13001
2022
Q4 		$15.3K Buy
+5,109
New +$20.3K ﹤0.01% 11844
2022
Q2 		– Sell
-2,126
Closed -$19K – 13370
2022
Q1 		$19K Buy
+2,126
New +$17.1K ﹤0.01% 12634

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's IKT Position: Q2 2026 in Review

Jeff Yass reduced its Inhibikase Therapeutics (IKT) stake by 54% in Q2 2026, selling an estimated $33.8K and leaving 16,242 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #12940.

Jeff Yass first reported a position in IKT in Q1 2022 and has held it in 9 quarters since. The position peaked at $1.11M in Q1 2025. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Jeff Yass held 16,242 shares of Inhibikase Therapeutics worth $33K as of Q2 2026.
  • Jeff Yass sold 18,858 Inhibikase Therapeutics shares in Q2 2026, an estimated $33.8K.
  • Inhibikase Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12940 holding.
  • Jeff Yass first reported a position in Inhibikase Therapeutics in Q1 2022 and has held it in 9 quarters since.
  • Jeff Yass's Inhibikase Therapeutics position peaked at $1.11M in Q1 2025.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.